Loading...

Aclaris Therapeutics, Inc.

ACRS•NASDAQ
Healthcare
Medical - Diagnostics & Research
$4.30
$-0.25(-5.49%)
U.S. Market opens in 23h 5m

Aclaris Therapeutics, Inc. (ACRS) Stock Overview

Explore Aclaris Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap518.6M
P/E Ratio-8.15
EPS (TTM)$-0.53
ROE-0.52%
Fundamental Analysis

AI Price Forecasts

1 Month$2.47
3 Months$1.86
1 Year Target$2.42

ACRS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Aclaris Therapeutics, Inc. (ACRS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.22, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.42.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.15 and a market capitalization of 518.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-5.49%
5-Day Change
4.88%
1-Month Change
30.30%
3-Month Change
-4.44%
6-Month Change
100.00%
Year-to-Date (YTD) Change
42.86%
1-Year Change
238.58%
3-Year Change
-52.64%
5-Year Change
-83.50%
All-Time (Max) Change
-60.91%

Contact Information

https://www.aclaristx.com
484 324 7933
640 Lee Road, Wayne, PA, 19087

Company Facts

61 Employees
IPO DateOct 6, 2015
CountryUS
Actively Trading

Frequently Asked Questions